How Will The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Expand At A CAGR Of 9.5% Through 2029?
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
How Big Is The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Today And What Is Its Future Size?
The market for nucleic acid and gene therapies for neuromuscular disorders has experienced robust growth in recent years. The market value is predicted to rise from $6.84 billion in 2024 to $7.5 billion in 2025, boasting a compound annual growth rate (CAGR) of 9.6%. This significant growth in the past can be credited to several factors including higher regulatory approvals, rising demand for nucleic acid therapies, increasing need for more accurate and potent treatments, rising demand for potent gene therapies, and the surge in gene-therapy related findings.
As we look ahead, the market for nucleic acid and gene therapies in neuromuscular disorders is predicted to observe strong growth. It is projected to expand to $10.78 billion by 2029, with a compound annual growth rate of 9.5%. Factors contributing to this growth in the predicted period include higher prevalence of genetic disorders, additional investment in research and development, increased demand for precision medicine, growing approval of gene therapy products, and a rise in chronic disorders. Key trends for the forecast period include better patient care, high-performance chromatography, novel solutions for conditions, development in gene editing technologies, and access to nucleic acid extraction technology.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21233&type=smp
What External And Internal Drivers Are Influencing The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?
The rise in cases of genetic disorders is anticipated to fuel the expansion of the nucleic acid and gene therapies in the neuromuscular disorders market. These disorders stem from abnormalities in a person’s DNA, whether inherited or mutated. A combination of genetic mutations, environmental factors, lifestyle shifts, and enhanced diagnostic techniques has led to a surge in these disorders. Nucleic acid and gene therapies are instrumental in combating genetic disorders by fixing or updating faulty genes in neuromuscular circumstances, thereby restoring usual function. For example, data from Cure SMA, a US-based non-profit entity, showed that between 9,000 and 9,500 individuals are living with Spinal Muscular Atrophy (SMA) in the United States as of May 2024. 37% of these individuals are diagnosed with Type 2 SMA, with the condition occurring in 1 out of every 15,000 births. Thus, the escalating presence of genetic disorders is accelerating the growth of the nucleic acid and gene therapies in the neuromuscular disorders market.
How Is The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Categorized Across Applications And Types?
The nucleic acid and gene therapies in neuromuscular disordersmarket covered in this report is segmented –
1) By Disorder: Motor Neuron Diseases; Neuropathies; Neuromuscular Junction Disorders; Myopathies Including Muscular Dystrophies
2) By Therapy: Adeno-Associated Viruses Gene Therapy; Postnatal Gene Therapy; Spinal Muscular Atrophy
3) By Application: Hospitals; Specialty Clinics; Ambulatory Surgery Centers
Subsegments:
1) By Motor Neuron Diseases: Amyotrophic Lateral Sclerosis (ALS); Spinal Muscular Atrophy (SMA); Primary Lateral Sclerosis (PLS)
2) By Neuropathies: Charcot-Marie-Tooth Disease (CMT); Hereditary Sensory and Autonomic Neuropathy (HSAN); Peripheral Neuropathies
3) By Neuromuscular Junction Disorders: Myasthenia Gravis; Lambert-Eaton Myasthenic Syndrome (LEMS)
4) By Myopathies Including Muscular Dystrophies: Duchenne Muscular Dystrophy (DMD); Becker Muscular Dystrophy (BMD); Limb-Girdle Muscular Dystrophy (LGMD); Facioscapulohumeral Muscular Dystrophy (FSHD)
Which Emerging Trends Are Reshaping The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Landscape?
In the nucleic acid and gene therapies for neuromuscular disorders market, companies are focusing on gene therapies targeting genetic causes by correcting or replacing defective genes. Gene therapy involves modifying genetic material within cells to treat diseases. For example, in June 2023, Sarepta Therapeutics Inc., a US biotech company, gained FDA approval for Elevidys, the first gene therapy for Duchenne Muscular Dystrophy in ambulatory pediatric patients aged 4 to 5 years. Delivered as a single intravenous infusion, Elevidys introduces a gene coding for micro-dystrophin, a shortened but functional dystrophin essential for muscle function, potentially halting or reversing disease progression.
Who Are The Global Leaders Steering The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Forward?
Major companies operating in the nucleic acid and gene therapies in neuromuscular disorders market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Sanofi S.A, Novartis AG, Eli Lilly and Company, Astellas Pharma Inc, Biogen Inc, Vertex Pharmaceuticals Inc, BioMarin Pharmaceuticals Inc, Nippon Shinyaku Co Ltd, Sarepta Therapeutics Inc, Ionis Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc, Amicus Therapeutics Inc, Arrowhead Pharmaceuticals Inc, Regenxbio Inc, UniQure N.V., Généthon S.A, Axovant Gene Therapies Inc.
Access The Complete Report Here:
What Are The Emerging Regional Trends Driving The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?
North America was the largest region in the nucleic acid and gene therapies in neuromuscular disorders market in 2024. The regions covered in the nucleic acid and gene therapies in neuromuscular disorders market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=21233&type=smp
Browse Through More Reports Similar to the Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market 2025, By The Business Research Company
Isothermal Nucleic Acid Amplification Technology Global Market Report 2025
Nucleic Acid Based Gene Therapy Global Market Report 2025
Nucleic Acid Isolation And Purification Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
